AlphAIAlphAI — Financial news for AI agents
manilatimes.netJUN 51 min read$NBTX

Voting Rights and Shares Capital of the Company

Nanobiotix reported its voting rights as of May 31, 2026: 50,807,903 shares outstanding, with 54,304,858 total theoretical voting rights and 54,282,740 exercisable voting rights. The filing cites French Commercial Code L.233-8 II and AMF rules on gross and net voting-right calculations, relevant for threshold monitoring on Euronext Paris and Nasdaq.

Original reporting
manilatimes.net
Published Jun 5, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Voting Rights and Shares Capital of the Company — source image
Source · manilatimes.net
Decision brief

The 30-second read

$NBTXNeutralLow
01

Why it matters

This updates governance metrics used for threshold crossings; it does not provide new clinical trial results, financing terms, or corporate actions.

02

Market read

Primarily administrative; useful for investors tracking voting-rights thresholds and meeting-related calculations.

03

What to watch

Without accompanying shareholder stake changes or corporate actions, the disclosure is unlikely to drive liquidity or sentiment.

Relevance 4/10Novelty 3/10Timing: as-of May 31 voting-rights update; published June 5

Background

The article is a regulatory disclosure under French Commercial Code/AMF rules reporting total voting rights (theoretical and exercisable) and shares outstanding as of May 31, 2026.

Company-level read

Ticker impact

$NBTXNeutralMedium confidence
Context

Nanobiotix discloses its voting rights and total shares outstanding as of May 31, 2026, a regulatory threshold metric for NBTX.

Expected impact

Low/immaterial near-term; any move would be limited to technical positioning around governance thresholds.

Evidence & confidence

The release is a French/AMF-compliance update of voting rights counts (theoretical vs exercisable) rather than new clinical, financial, or deal information.

Market effects

Sector

Minimal; governance/float mechanics are company-specific and do not change sector fundamentals.

Regional

Limited to Euronext Paris/Nasdaq cross-listing compliance optics.

Global

Low; primarily affects threshold-tracking and shareholder meeting calculations.

Counterpoint

What could challenge this read

Traders focused on ownership-threshold triggers could treat this as a check for potential future filings, but the article itself contains no new ownership change.

Key entities

  • issuer
    Nanobiotix

    Late-stage clinical biotechnology company listed on Euronext Paris and Nasdaq (NBTX).

  • regulator
    AMF (Autorité des Marchés Financiers)

    French financial markets authority referenced for voting-rights calculation rules.

Read at source← All news

Related articles

OCT 24
$NBTXHighAI 8/10

A 24-person study of treatment-resistant melanoma reported median survival of 17.8 months.

Nanobiotix (Euronext: NANO, NASDAQ: NBTX) presented Phase 1 study results showing 41.7% ORR and 17.8-month median survival in 24 advanced melanoma patients treated with JNJ-1900 (NBTXR3) and immunotherapy. The treatment demonstrated an acceptable safety profile and potential immune activation, warranting further trials. Data were shared at the 2026 ESMO Congress.

stocktitan.net2 min
SEP 24
$NBTXHigh

Nanobiotix S.A. (NBTX): Financial results for H1 2026

Nanobiotix S.A. (NBTX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 NANOBIOTIX Provides First Half 2026 Operational and Financial Update Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoreg

SEC EDGAR 6-K3 min
MAY 26
$NBTXHighAI 9/10

NANOBIOTIX Announces Closing of Global Offering

Nanobiotix said it has closed its global offering, including the underwriters’ option for additional shares/ADSs. After full option exercise, it issued 2,218,467 ordinary shares (225,373 ADSs plus 33,805 additional ADSs) and 345,099 pre-funded warrants, raising about $100 million (€86.1 million) gross. Net proceeds will fund JNJ-1900 (<10%), Nanoprimer (50–60%), and general purposes (30–40%).

manilatimes.net2 min
OCT 24
$INTCMed

Intel semiconductors granted one-year waiver to robotics ban

The FCC granted Intel a one-year waiver to use foreign-made robotics in its U.S. semiconductor production. The waiver allows Intel to continue operating its Automated Guided Vehicles (AGVs), which are critical to its chip manufacturing. Intel cited a lack of domestic alternatives and the potential disruption to its supply chain if it had to replace the AGVs. The FCC's quick approval and Intel's importance to U.S. chip manufacturing plans are noted.

dig.watch2 min
OCT 24
$CMed

Citi Receives Approval from the China Securities Regulatory Commission to Establish A Wholly-Owned Securities Company in China, Citigroup Securities Company Limited

Citi received approval from China's CSRC to establish a wholly-owned securities firm, Citigroup Securities (China) Company Limited (CSCCL). The license allows CSCCL to offer equities brokerage, underwriting, research, and trading services. Citi will complete regulatory procedures for operations to begin. CSCCL, based in Shanghai, will serve domestic and foreign clients with onshore capital markets services.

marketscreener.com1 min